PD(L)1 inhibitors have demonstrated efficacy in various solid tumors, although not in pancreatic cancer (4); however, chemotherapy used in patients with pancreatic cancer may promote immunogenic cell death, and preclinical studies and preliminary clinical reports provide evidence for the rationale to combine chemotherapy with PD(L)1 inhibitors in these patients (2). This evidence concerns the gene CD274 and pancreatic neoplasm.